单纯药物涂层球囊在冠状动脉介入治疗中的研究进展

doi:10.3969/j.issn.1004-583X.2026.02.016

摘要/Abstract

摘要：

药物涂层球囊(drug-coated balloon, DCB)作为冠心病介入治疗的新型策略,被广泛用来与药物洗脱支架(drug-eluting stent, DES)进行治疗效果的对比。本文回顾了DES增加患者远期不良事件的风险,对于复杂病变DES的成功植入存在挑战等相关问题,介绍了DCB通过局部释放抗增殖药物(如紫杉醇或西罗莫司)抑制血管内膜增生,避免了永久性支架植入,从而减少患者远期不良事件发生等优势。归纳国内外研究表明,与DES相比,DCB在治疗小血管疾病和复杂冠状动脉病变时可显著降低支架血栓形成及出血并发症的发生率,表现出良好的安全性。通过综述国内外相关研究,探讨了DCB在AMI患者中作为初始治疗策略的可行性,重点分析其在改善血管再通、减少晚期血管事件及改善心功能方面的潜在优势。本文指出DCB在冠状动脉介入治疗中展现了良好的前景,但仍需未来的研究进一步探讨其在不同类型患者中的临床应用,旨在为DCB在冠心病介入治疗中的进一步应用提供理论参考。

关键词: 心肌梗死, 单纯药物涂层球囊, 药物洗脱支架, 经皮冠状动脉介入治疗, 冠状动脉粥样硬化性心脏病

中图分类号:

R542.22

郝清卿, 张飞飞, 吕仕林. 单纯药物涂层球囊在冠状动脉介入治疗中的研究进展[J]. 临床荟萃, 2026, 41(2): 188-192.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.02.016

https://www.lchc.cn/CN/Y2026/V41/I2/188

参考文献 37

[1]	Mensah GA, Fuster V, Murray CJL, et al. Global burden of cardiovascular diseases and risks, 1990-2022[J]. J Am Coll Cardiol, 2023, 82(25): 2350-2473. doi: 10.1016/j.jacc.2023.11.007. pmid: 38092509
[2]	Takeuchi M, Dohi T, Fukase T, et al. Comparison of clinical outcomes between percutaneous coronary intervention for the de novo lesion versus in-stent restenosis lesion[J]. Eur Heart J, 2021, 42(Supplement 1). doi: 10.1007/s12928-021-00792-5.
[3]	Giustino G, Colombo A, Camaj A, et al. Coronary in-stent restenosis[J]. J Am Coll Cardiol, 2022, 80(4): 348-372. doi: 10.1016/j.jacc.2022.05.017. pmid: 35863852
[4]	Korjian S, McCarthy KJ, Larnard EA, et al. Drug-coated balloons in the management of coronary artery disease[J]. Circ Cardiovasc Interv, 2024, 17(5). doi: 10.1161/CIRCINTERVENTIONS.123.013302.
[5]	Muramatsu T, Kozuma K, Tanabe K, et al. Clinical expert consensus document on drug-coated balloon for coronary artery disease from the Japanese Association of Cardiovascular Intervention and Therapeutics[J]. Cardiovasc Interv Ther, 2023, 38(2): 166-176. doi: 10.1007/s12928-023-00921-2.
[6]	中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国慢性冠脉综合征患者诊断及管理指南[J]. 中华心血管病杂志, 2024, 52(6): 589-614. doi: 10.3760/cma.j.cn112148-20240325-00168.
[7]	Van Hemert ND, Stella PR, Rozemeijer R, et al. High bleeding risk in patients undergoing percutaneous coronary intervention with drug-eluting stent implantation: ReCre8 subanalysis[J]. Am Heart J Plus, 2022, 24: 100227. doi: 10.1016/j.ahjo.2022.100227.
[8]	Somsen YBO, Rissanen TT, Hoek R, et al. Application of drug-coated balloons in complex high risk and indicated percutaneous coronary interventions[J]. Catheter Cardiovasc Interv, 2025, 105(2): 494-516. doi: 10.1002/ccd.31316.
[9]	Rheude T, Fitzgerald S, Allali A, et al. Rotational atherectomy or balloon-based techniques to prepare severely calcified coronary lesions[J]. JACC Cardiovasc Interv, 2022, 15(18). doi: 10.1016/j.jcin.2022.07.034.
[10]	Stone GW, Christiansen EH, Ali ZA, et al. Intravascular imaging-guided coronary drug-eluting stent implantation: An updated network meta-analysis[J]. Lancet, 2024, 403(10429): 824-837. doi: 10.1016/S0140-6736(23)02454-6. pmid: 38401549
[11]	Verde N, Ciliberti G, Pittorino L, et al. Contemporary use of drug-coated balloons for coronary angioplasty: A comprehensive review[J]. J Clin Med, 2024, 13(20): 6243. doi: 10.3390/jcm13206243.
[12]	Bhogal S, Hill AP, Merdler I, et al. Drug-coated balloons for coronary artery disease: An updated review with future perspectives[J]. Cardiovasc Revasc Med, 2024. doi: 10.1016/j.carrev.2024.05.027.
[13]	Yerasi C, Case BC, Forrestal BJ, et al. Drug-coated balloon for de novo coronary artery disease: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 75(9): 1061-1073. doi: 10.1016/j.jacc.2019.12.046.
[14]	Zhao K, Guo Q, Zhao Z, et al. Clinical value of drug-coated balloon versus second-generation drug-eluting stent for de novo lesions in large coronary arteries: Insights from the real world[J]. BMC Cardiovasc Disord, 2024, 24(1): 1-10. doi: 10.1186/s12872-024-04386-w.
[15]	Ahmed S, Ahmad E, Ahmed M, et al. Paclitaxel-coated balloon catheter versus paclitaxel-eluting stent for the treatment of coronary in-stent restenosis: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials[J]. Medicine (Baltimore), 2025, 104(15): e42113. doi: 10.1097/MD.0000000000042113.
[16]	Al-Abdouh A, Samadi D, Sukhon F, et al. Paclitaxel-coated balloon versus uncoated balloon angioplasty for coronary in-stent restenosis: A systematic review and meta-analysis of randomized controlled trials[J]. Am J Cardiol, 2024, 231: 82-89. doi: 10.1016/j.amjcard.2024.08.028. pmid: 39222739
[17]	Yeh RW, Shlofmitz R, Moses J, et al. Paclitaxel-coated balloon vs uncoated balloon for coronary in-stent restenosis: The AGENT IDE randomized clinical trial[J]. JAMA, 2024, 331(12). doi: 10.1001/jama.2024.1361.
[18]	Nakamura M, Isawa T, Nakamura S, et al. One-year safety and effectiveness of the Agent paclitaxel-coated balloon for the treatment of small vessel disease and in-stent restenosis[J]. Cardiovasc Interv Ther, 2024, 39(1). doi: 10.1007/s12928-023-00953-8.
[19]	Tang Y, Qiao S, Su X, et al. Drug-coated balloon versus drug-eluting stent for small-vessel disease: The RESTORE SVD China randomized trial[J]. JACC Cardiovasc Interv, 2018, 11(23). doi: 10.1016/j.jcin.2018.09.009.
[20]	Yerasi C, Case BC, Forrestal BJ, et al. Drug-coated balloon for de novo coronary artery disease: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 75(9). doi: 10.1016/j.jacc.2019.12.046.
[21]	Li Y, Mao Q, Liu H, et al. Effect of paclitaxel-coated balloon angioplasty on side branch lesion and cardiovascular outcomes in patients with de novo true coronary bifurcation lesions undergoing percutaneous coronary intervention[J]. Cardiovasc Drugs Ther, 2022, 36(5). doi: 10.1007/s10557-021-07225-8.
[22]	Eftekhari A, Jensen OL, Veien K, et al. Biolimus-eluting biomatrix stent versus a dual-therapy sirolimus-eluting stent in PCI: SORT OUT XI randomized trial[J]. J Am Coll Cardiol, 2025. doi: 10.1016/j.jacc.2025.05.012.
[23]	Gurgoglione FL, De Gregorio M, Benatti G, et al. Paclitaxel-coated versus sirolimus-coated eluting balloons for percutaneous coronary interventions: Pharmacodynamic properties, clinical evidence, and future perspectives[J]. Future Pharmacol, 2024, 4(4): 775-787. doi: 10.3390/futurepharmacol4040041 URL
[24]	Cortese B, Testa L, Heang TM, et al. Sirolimus-coated balloon in an all-comer population of coronary artery disease patients: The EASTBOURNE prospective registry[J]. JACC Cardiovasc Interv, 2023, 16(14). doi: 10.1016/j.jcin.2023.05.005.
[25]	Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter[J]. N Engl J Med, 2006, 355(20): 2113-2124. doi: 10.1056/NEJMoa061254.
[26]	Pan L, Lu W, Han Z, et al. Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: A patient-level propensity-matched analysis[J]. Front Cardiovasc Med, 2022, 9: 1028007. doi: 10.3389/fcvm.2022.1028007.
[27]	Uskela S, Kärkkäinen JM, Eränen J, et al. Percutaneous coronary intervention with drug-coated balloon-only strategy in stable coronary artery disease and in acute coronary syndromes: An all-comers registry study[J]. Catheter Cardiovasc Interv, 2019, 93(5): 893-900. doi: 10.1002/ccd.27950.
[28]	Qin Q, Chen L, Ge L, et al. Long-term clinical outcomes of drug-coated balloon for the management of chronic total occlusions[J]. Coron Artery Dis, 2023, 34(8): 555. doi: 10.1097/MCA.0000000000001288.
[29]	Unverdorben M, Kleber FX, Heuer H, et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: Are lesions clinically stable from 12 to 36 months?[J]. EuroIntervention, 2013, 9(5): 620-628. doi: 10.4244/EIJV9I5A99. pmid: 24058078
[30]	Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J, 2014, 35(37). doi: 10.1093/eurheartj/ehu278.
[31]	Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes[J]. Eur Heart J, 2023, 44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.
[32]	Nijhoff F, Agostoni P, Belkacemi A, et al. Primary percutaneous coronary intervention by drug-eluting balloon angioplasty: The nonrandomized fourth arm of the DEB-AMI (drug-eluting balloon in ST-segment elevation myocardial infarction) trial[J]. Catheter Cardiovasc Interv, 2015, 86: S34-S44. doi: 10.1002/ccd.25603.
[33]	Vos NS, Dirksen MT, Vink MA, et al. Safety and feasibility of a paclitaxel-eluting balloon angioplasty in primary percutaneous coronary intervention in Amsterdam (PAPPA): One-year clinical outcome of a pilot study[J]. EuroIntervention, 2014, 10(5): 584-590. doi: 10.4244/EIJV10I5A101. pmid: 25256200
[34]	Vos NS, Van Der Schaaf RJ, Amoroso G, et al. Revascularization with paclitaxel-coated balloon angioplasty versus drug-eluting stenting in acute myocardial infarction-a randomized controlled trial: Rationale and design of the REVELATION trial[J]. Catheter Cardiovasc Interv, 2016, 87(7): 1213-1221.
[35]	Vos NS, Fagel ND, Amoroso G, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction[J]. JACC Cardiovasc Interv, 2019, 12(17): 1691-1699. doi: 10.1016/j.jcin.2019.04.016.
[36]	Niehe SR, Vos NS, Van Der Schaaf RJ, et al. 5-Year clinical outcomes of paclitaxel-coated balloon angioplasty vs DES in acute MI: The REVELATION trial[J]. JACC Cardiovasc Interv, 2024, 17(9): 1185-1186. doi: 10.1016/j.jcin.2024.03.012.
[37]	Gao C, He X, Ouyang F, et al. Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): An open-label, randomised, non-inferiority trial[J]. Lancet, 2024, 404(10457): 1040-1050. doi: 10.1016/S0140-6736(24)01594-0. pmid: 39236727